Navigation Links
Preventive cancer surgeries save women's lives
Date:8/31/2010

CHICAGO --- A new study underscores the importance for women with a family history of breast or ovarian cancer to get genetic counseling and testing for the BRCA1 and BRCA2 genes that make them more likely to develop lethal breast or ovarian cancer, says a Northwestern Medicine oncologist.

The study, which will be published in the Sept. 1 issue of the Journal of the American Medical Association (JAMA), shows women with the gene live longer and nearly eliminate their risk of cancer by having prophylactic surgeries to remove their ovaries and fallopian tubes (salpingo-oophorectomy) or their breasts in a mastectomy.

"This is the first study to prove women survive longer with these preventive surgeries and shows the importance of genetic testing when there is a family history of early breast or ovarian cancer," said Virginia Kaklamani, M.D., co-author of an accompanying editorial in JAMA. Kaklamani is director of translational breast cancer research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. She also is an associate professor of medicine at Northwestern University Feinberg School of Medicine and an oncologist at Northwestern Memorial Hospital.

In the editorial, Kaklamani and coauthor, Laura Esserman, M.D., a physician at the University of California, San Francisco, describe what the findings mean to women and their physicians.

"Primary care physicians, gynecologists and women need to be more aware that these tests exist," Kaklamani said. "So if a woman has a family history of ovarian cancer or breast cancer, the woman can be genetically tested. Testing should not start with the oncologists. That's when patients already have breast cancer. The primary care doctors and gynecologists are the ones who should evaluate patients and offer them genetic counseling."

About 10 to 20 percent of breast and ovarian cancers are due to BRCA1 or BRCA2 genes. "Most of these women will die of ovarian cancer, so you can save 20 percent of them with the prophylactic surgery," Kaklamani said. "And you can save the majority of women who would have died of their breast cancer."

Even women diagnosed with breast or ovarian cancer can still benefit from genetic testing "because the presence of a mutation significantly increases the risk of a second primary (breast or ovarian) diagnosis and often influences the choice of treatments," the authors write.

While some women diagnosed with the gene mutation may opt for surveillance with an alternating mammogram and breast magnetic resonance imaging every six months, the authors emphasize surveillance is not prevention. And, ovarian cancer screening has limited value.

Women should be aware that options for these preventive surgeries have improved, the authors note. A laparoscopic salpingo-oophorectomy is a relatively low-risk procedure and can be done in an out-patient setting. And cosmetic options for women getting mastectomies have greatly improved.


'/>"/>

Contact: Marla Paul
marla-paul@northwestern.edu
312-503-8928
Northwestern University
Source:Eurekalert

Related medicine news :

1. New Private Health Plans Must Offer Preventive Care
2. Summit Health, U.S. Preventive Medicine Agree to Continue Worksite Screening Partnership
3. Lab Industry Likely to Benefit from Expanded Preventive Testing Under New Health Care Law
4. U.S. Preventive Medicine Helps Participants of the State of Nevada Public Employees' Benefits Program (PEBP) Become Healthier
5. Device to revolutionize preventive blood clot care after joint replacement surgery
6. Preventive Mastectomy May Not Lower Risks
7. Preventive behaviors limited household transmission of H1N1 influenza during initial outbreak
8. Pet Dental Month Prime Time To Schedule Preventive Annual Cleaning For Pets
9. Can Fruits, Veggies Help Ward Off Lung Cancer?
10. Increasing selenium intake may decrease bladder cancer risk
11. Diverse diet of veggies may decrease lung cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/24/2017)... ... ... Millions of families and businesses worldwide depend on high quality water from ... water. However, well water can also become contaminated with bacteria and odors from flood ... The EPA does not regulate private drinking water wells. Many states and towns do ...
(Date:9/24/2017)... ... ... boy was walking home and feeling down about himself. He didn’t think he was good ... he can do whatever he wants to do if he puts his mind to it. ... God created him with special talents and gifts. We see his internal dialogue change. He ...
(Date:9/24/2017)... ... ... The Other Sheep”: the ceremonial laws of Moses and the Holy Law of God reexamined. ... author, Maurice Caines. Maurice Caines resides in the sunny isle of Florida, but he ... Adventist Church for many years. He was previously a member of the Anglican Church ...
(Date:9/23/2017)... San Francisco, CA (PRWEB) , ... September 23, 2017 , ... ... Bay Area, is proud to announce a new blog post focused on the ARTAS® ... loss, they understandably hope to turn to the latest, most technologically sophisticated methods of ...
(Date:9/22/2017)... Albert Lea, MN (PRWEB) , ... September 22, 2017 , ... ... and video) at its rally to interview citizens on why they are rallying against ... stories and commitment to this effort against Dr. Noseworthy’s (CEO) decision to close the ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... 2017  Eli Lilly and Company (NYSE: ... data for lasmiditan, an investigational, oral, first-in-class molecule for ... improvements compared to placebo in the Phase 3 SPARTAN ... 18th Congress of the International Headache Society (IHC) in ... presented today demonstrate lasmiditan,s potential to reduce pain and ...
(Date:9/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... will be participating in the Morgan Stanley 15 th ... hotel in New York.  Zimmer Biomet will present on ... A live webcast of the presentation can ... http://investor.zimmerbiomet.com .   ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
Breaking Medicine Technology: